See more : Delta Corp Limited (DELTACORP.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Adicet Bio, Inc. (ACET) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adicet Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Energy Transfer LP (ET-PE) Income Statement Analysis – Financial Results
- Redwood Pharma AB (REDW.ST) Income Statement Analysis – Financial Results
- Ginkgo Bioworks Holdings, Inc. (DNA) Income Statement Analysis – Financial Results
- American Resources Corporation (AREC) Income Statement Analysis – Financial Results
- Eastern Media International Corporation (2614.TW) Income Statement Analysis – Financial Results
Adicet Bio, Inc. (ACET)
About Adicet Bio, Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 24.99M | 9.73M | 17.90M | 995.00K | 8.18M | 558.52M | 546.95M | 510.18M | 499.69M | 499.69M | 444.39M | 412.43M | 346.63M | 322.65M | 359.59M |
| Cost of Revenue | 6.10M | 5.01M | 0.00 | 0.00 | 125.00K | 80.00K | 5.00K | 411.52M | 395.48M | 401.42M | 401.42M | 362.36M | 346.59M | 292.48M | 267.03M | 292.29M |
| Gross Profit | -6.10M | 19.98M | 9.73M | 17.90M | 870.00K | 8.10M | 558.52M | 135.43M | 114.70M | 98.27M | 98.27M | 82.03M | 65.84M | 54.16M | 55.62M | 67.31M |
| Gross Profit Ratio | 0.00% | 79.96% | 100.00% | 100.00% | 87.44% | 99.02% | 100.00% | 24.76% | 22.48% | 19.67% | 19.67% | 18.46% | 15.96% | 15.62% | 17.24% | 18.72% |
| Research & Development | 106.04M | 71.25M | 48.94M | 34.33M | 23.69M | 14.72M | 16.84M | 5.94M | 5.22M | 2.83M | 0.00 | 0.00 | 0.00 | 0.00 | 153.00K | 506.00K |
| General & Administrative | 26.53M | 26.30M | 22.22M | 22.76M | 8.69M | 8.43M | 76.82M | 73.16M | 65.21M | 61.02M | 63.86M | 56.67M | 49.29M | 44.72M | 43.57M | 45.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -74.78M | -73.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.53M | 26.30M | 22.22M | 22.76M | 8.69M | 8.43M | 2.04M | 1.00K | 65.21M | 61.02M | 63.86M | 56.67M | 49.29M | 44.72M | 43.57M | 45.42M |
| Other Expenses | 19.46M | -919.00K | -606.00K | -953.00K | 2.33M | 4.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 152.04M | 97.54M | 71.16M | 57.09M | 32.38M | 23.15M | 18.88M | 1.00K | 70.43M | 63.86M | 63.86M | 56.67M | 49.29M | 44.72M | 43.73M | 45.93M |
| Cost & Expenses | 152.04M | 97.54M | 71.16M | 57.09M | 32.38M | 23.15M | 18.88M | 1.00K | 465.91M | 465.27M | 465.27M | 419.02M | 395.88M | 337.19M | 310.75M | 338.21M |
| Interest Income | 9.95M | 3.76M | 91.00K | 785.00K | 938.00K | 543.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 80.00K | 176.00K | 134.00K | 0.00 | 0.00 | 7.00M | 3.95M | 2.10M | 2.12M | 2.12M | 2.63M | 1.57M | 230.00K | 98.00K | 145.00K |
| Depreciation & Amortization | 6.10M | 5.01M | 4.07M | 1.95M | 1.24M | 80.00K | 5.00K | 11.85M | 8.09M | 6.94M | 6.94M | 6.94M | 5.50M | 2.80M | 1.87M | 2.38M |
| EBITDA | -136.54M | -64.70M | -60.41M | -37.41M | -26.88M | -13.74M | -33.77M | -1.00K | 54.87M | 43.62M | 43.62M | 34.31M | 24.03M | 13.23M | 14.70M | 24.71M |
| EBITDA Ratio | 0.00% | -278.95% | -636.67% | -219.85% | -2,701.61% | -105.93% | -3.38% | 0.00% | 10.75% | 8.73% | 8.73% | 7.72% | 5.83% | 3.82% | 4.55% | 6.87% |
| Operating Income | -152.04M | -72.55M | -61.43M | -39.19M | -31.39M | -14.96M | -18.88M | -1.00K | 44.27M | 34.42M | 34.42M | 25.37M | 16.55M | 9.44M | 11.89M | 21.38M |
| Operating Income Ratio | 0.00% | -290.32% | -631.38% | -218.91% | -3,154.57% | -182.91% | -3.38% | 0.00% | 8.68% | 6.89% | 6.89% | 5.71% | 4.01% | 2.72% | 3.69% | 5.94% |
| Total Other Income/Expenses | 9.38M | 2.76M | -691.00K | -302.00K | 3.27M | 5.08M | -14.90M | 0.00 | 402.00K | 134.00K | 134.00K | -626.00K | 412.00K | 765.00K | 839.00K | 812.00K |
| Income Before Tax | -142.66M | -69.79M | -62.12M | -39.49M | -28.12M | -9.89M | -33.78M | -1.00K | 44.67M | 34.55M | 34.55M | 24.74M | 16.96M | 10.20M | 12.73M | 22.19M |
| Income Before Tax Ratio | 0.00% | -279.27% | -638.48% | -220.59% | -2,826.03% | -120.87% | -6.05% | 0.00% | 8.76% | 6.91% | 6.91% | 5.57% | 4.11% | 2.94% | 3.95% | 6.17% |
| Income Tax Expense | 0.00 | -2.76M | -125.00K | -2.82M | 19.00K | -589.00K | 19.09M | 20.38M | 15.67M | 12.22M | 12.22M | 7.76M | 7.99M | 3.62M | 4.10M | 8.72M |
| Net Income | -142.66M | -67.03M | -62.00M | -36.68M | -28.14M | -9.30M | -33.78M | -1.00K | 29.00M | 22.33M | 22.33M | 16.98M | 8.97M | 6.58M | 8.63M | 13.47M |
| Net Income Ratio | 0.00% | -268.22% | -637.19% | -204.87% | -2,827.94% | -113.67% | -6.05% | 0.00% | 5.68% | 4.47% | 4.47% | 3.82% | 2.17% | 1.90% | 2.67% | 3.75% |
| EPS | -3.31 | -1.63 | -2.00 | -5.01 | -1.52 | -0.31 | -1.26 | 0.00 | 1.18 | 0.94 | 0.94 | 0.73 | 0.40 | 0.30 | 0.40 | 0.63 |
| EPS Diluted | -3.31 | -1.63 | -2.00 | -5.01 | -1.52 | -0.31 | -1.25 | 0.00 | 1.16 | 0.93 | 0.93 | 0.72 | 0.39 | 0.30 | 0.39 | 0.62 |
| Weighted Avg Shares Out | 43.04M | 41.08M | 30.95M | 7.32M | 18.56M | 29.80M | 26.77M | 28.05M | 24.50M | 23.67M | 23.67M | 23.26M | 22.67M | 21.86M | 21.43M | 21.30M |
| Weighted Avg Shares Out (Dil) | 43.04M | 41.08M | 30.95M | 7.32M | 18.56M | 29.80M | 26.97M | 28.05M | 24.99M | 24.02M | 24.02M | 23.46M | 22.84M | 22.07M | 21.86M | 21.70M |
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and AlloVir, Inc. (ALVR) have performed compared to their sector so far this year.
Down -53.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Adicet Bio, Inc. (ACET)
Adicet Bio, Inc. (ACET) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal...
5 Stocks to Pop Surprise Returns From Secret Santa
Adicet Bio (ACET), Enfusion (ENFN), Dillard's (DDS), First BanCorp. (FBP) and Hillenbrand (HI) could bring gifts of surprise returns from Secret Santa.
Adicet Bio, Inc. (ACET) Loses 47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Adicet Bio, Inc. (ACET) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Why The Adicet Bio (ACET) Stock Plummeted Over 35%
The stock price of Adicet Bio (ACET) plummeted over 35% intraday today. This is why.
Adicet Bio shares fall as it shares clinical data about its CAR-T treatment candidate
Adicet Bio's Inc. ACET, -13.13% stock tumbled about 38% in premarket trading on Monday after the company shared data from a Phase 1 clinical trial evaluating the company's investigational CAR-T therapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma....
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced positive safety and efficacy data from the Company’s ongoing Phase 1 study...
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
Here is how Adicet Bio, Inc. (ACET) and Merck (MRK) have performed compared to their sector so far this year.
What Makes Adicet Bio, Inc. (ACET) a Good Fit for 'Trend Investing'
Adicet Bio, Inc. (ACET) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a webcast presentation on Sunday,...
Source: https://incomestatements.info
Category: Stock Reports